Trust Signals
This page grades every claim by evidence tier. We concede where peptides lose to alternatives. No affiliate links influence the rankings below. This content is for informational purposes only and does not constitute medical advice.
Key Takeaways
- Tirzepatide (GLP-1/GIP dual agonist) produced roughly 20.2% body weight reduction vs. 13.7% for semaglutide in the direct head-to-head SURMOUNT-5 trial, the highest fat-loss numbers of any peptide with human RCT support.
- Tesamorelin is the only growth hormone secretagogue with FDA approval and peer-reviewed RCT data for visceral fat reduction, though approval is specific to HIV-associated lipodystrophy.
- CJC-1295 plus ipamorelin is the most studied non-approved GHRH/GHRP stack; ipamorelin's selectivity for GHSR-1a means lower cortisol and prolactin side effects than older GHRPs like GHRP-6.
- BPC-157 and TB-500 have zero completed human RCTs for fat loss or muscle growth as of mid-2025; all human claims are extrapolations from rodent or in-vitro data.
- Purity is the single largest uncontrolled variable in the research peptide market. An HPLC purity below 98% and absent endotoxin testing on a COA should disqualify a product.
What Are the Best Peptides for Fat Loss and Muscle Growth?
Table of Contents
- Evidence Ledger: Every Major Claim Graded
- How These Peptides Work: Mechanism With Real Numbers
- The Ranked List: 6 Peptides Assessed
- What Most Pages Get Wrong About This Category
- Honest Head-to-Head: Peptides vs. Real Alternatives
- Why the Storage and Stability Rules Exist
- Label and COA Literacy: How to Judge a Product
- Stacking Logic: When Combining Makes Sense
- FAQ
- Sources
What Evidence Exists for Each Peptide?
| Peptide | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Tirzepatide | Human RCT (SURMOUNT-1, n=2,539; SURMOUNT-5) | Strong fat loss, modest lean-mass preservation | High |
| Semaglutide 2.4 mg | Human RCT (STEP-1, n=1,961) | Significant fat loss (~14.9% body weight) | High |
| Tesamorelin | Human RCT (Falutz et al., n=412) | Visceral fat reduction ~15-18% in lipodystrophy | Moderate (specific population) |
| CJC-1295 / Ipamorelin | Small human pharmacokinetic studies; animal synergy data | GH/IGF-1 elevation; lean-mass preservation likely | Low to Moderate |
| MK-677 (Ibutamoren) | Small human RCTs (Nass et al., elderly cohorts) | IGF-1 elevation, lean-mass increase; fat mixed | Low (small n, specific populations) |
| BPC-157 | Animal studies only | Tendon/gut healing in rodents; fat loss speculative | Very Low for body comp claims |
| TB-500 (Thymosin Beta-4 fragment) | Animal and in-vitro | Wound healing; no body composition human data | Very Low |
How Do These Peptides Actually Work? Mechanism With Real Numbers
GLP-1 and GIP receptor agonists (Semaglutide, Tirzepatide). Native GLP-1 has a plasma half-life of roughly 2 minutes due to rapid DPP-4 cleavage. Semaglutide extends this to approximately 7 days by attaching a C18 fatty-diacid chain that enables reversible albumin binding, protecting it from DPP-4 and renal clearance. It acts on GLP-1 receptors in the hypothalamic arcuate nucleus and vagal afferents to reduce energy intake and slow gastric emptying. Tirzepatide adds GIP receptor co-agonism, which appears to potentiate adipocyte lipolysis and improve insulin sensitivity independently of GLP-1 signaling. That dual mechanism likely explains the incremental fat-loss advantage seen in SURMOUNT-5.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Caveat: These peptides reduce fat mass partly by reducing total caloric intake. They do not directly stimulate fat oxidation at the cellular level in a way that would operate independently of energy balance.
GHRH analogs and GHRPs (Tesamorelin, CJC-1295, Ipamorelin). Tesamorelin is a synthetic analog of endogenous GHRH, binding pituitary GHRH receptors to increase GH pulse amplitude. CJC-1295 without DAC (Modified GRF 1-29) mimics the same pathway with a half-life of roughly 30 minutes. CJC-1295 with DAC extends this to 6 to 8 days via a reactive maleimide group that forms a covalent bond with Cys-34 of albumin. Ipamorelin acts on the ghrelin receptor (GHSR-1a), increasing GH pulse frequency. Combining a GHRH analog with ipamorelin produces a synergistic GH release because the two mechanisms are independent and additive at the pituitary level. The downstream mediator is hepatic IGF-1, which drives skeletal muscle protein synthesis via the mTORC1 pathway.
Caveat: Elevated IGF-1 does not guarantee hypertrophy without a mechanical stimulus (resistance training). GH-axis stimulation in the absence of training redistributes body composition mildly; it does not create muscle de novo.
Which Specific Peptides Should You Consider, and Why?
1. Tirzepatide. Highest human RCT fat-loss data of any peptide. FDA-approved as Zepbound for obesity. Weekly subcutaneous injection. Appropriate for individuals with a clinical indication (BMI over 30, or over 27 with comorbidities). Not a performance-enhancement tool in lean, healthy individuals.
2. Semaglutide 2.4 mg (Wegovy). FDA-approved, well-tolerability profile established in large trials. Slightly lower fat-loss magnitude than tirzepatide at approved doses but longer post-market safety record. Also approved for cardiovascular risk reduction (SELECT trial, n=17,604).
3. Tesamorelin. Best evidence among non-GLP-1 peptides for visceral fat. FDA-approved but for a narrow indication. Off-label compounding occurs; efficacy data in non-lipodystrophy populations is limited to small pilot studies.
4. CJC-1295 without DAC plus Ipamorelin. The most commonly used research peptide stack for lean-mass preservation and GH optimization. Rationale is sound mechanistically. Human body composition RCTs are absent; lean-mass benefits are inferred from GH/IGF-1 elevation studies. Typical research doses range from 100 to 300 mcg per peptide, injected before sleep to align with endogenous GH pulsatility.
5. MK-677 (Ibutamoren). An orally active GHSR-1a agonist, technically not a peptide (it is a non-peptide ghrelin mimetic), but frequently grouped here. Small RCTs in elderly and GH-deficient populations show IGF-1 elevation and lean-mass preservation. Causes water retention and may worsen insulin sensitivity with chronic use.
6. BPC-157. Included because it is aggressively marketed for this category. The honest assessment: animal healing data is real and interesting. Body composition claims in humans are not supported by published RCTs. Do not pay a premium for fat-loss or muscle-growth claims on this compound.
What Do Most Pages Get Wrong About Peptides for Body Composition?
Bioavailability is almost never discussed honestly. Most peptides have negligible oral bioavailability because peptide bonds are cleaved by gastric proteases before absorption. Subcutaneous injection delivers roughly 70 to 90% of the dose systemically for most short peptides, but oral "peptide supplements" sold in capsule form provide essentially none of the intact peptide to circulation. When you see a collagen or "growth hormone-releasing" peptide in a drink or capsule, you are buying amino acids, not an active peptide.
The DAC confusion destroys dosing math. "CJC-1295" is sold as two completely different compounds depending on whether it contains the DAC modification. CJC-1295 with DAC and Modified GRF 1-29 (without DAC) have half-lives differing by a factor of roughly 16. Dosing them identically produces either undershooting or a prolonged pharmacological effect that blunts natural GH pulsatility. Most commodity pages never mention this.
Lean-mass loss on GLP-1 agonists is understated. DEXA sub-studies of semaglutide trials show that roughly 25 to 39% of lost weight may be lean mass, not fat. This is a genuine concern. Combining GLP-1 therapy with resistance training and adequate protein (1.6 to 2.2 g/kg body weight) mitigates but does not eliminate lean-mass loss. Pages that market semaglutide purely as a body recomposition tool omit this.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Comparison | Peptide | Alternative | Where Peptide Wins | Where Peptide Loses |
|---|---|---|---|---|
| Fat loss | Semaglutide 2.4 mg | Phentermine/topiramate ER | Cardiovascular safety data, GI tolerability profile, weekly dosing | Cost (semaglutide is 10x more expensive), some patients lose more weight on phentermine combinations |
| Visceral fat | Tesamorelin | Caloric restriction plus exercise | Preferentially targets visceral vs. subcutaneous fat; preserves lean mass | Requires daily injection, expensive, not approved for general population, visceral fat returns on cessation |
| Lean mass | CJC-1295/Ipamorelin stack | Resistance training (progressive overload) | May amplify GH pulsatility, may aid recovery | Resistance training has vastly more human evidence for muscle hypertrophy; stack is unregulated, purity unverified |
| Lean mass | MK-677 | Creatine monohydrate | IGF-1 elevation, may help elderly lean-mass retention | Creatine has more RCT support, costs less than $0.10/day, no insulin resistance risk |
| Healing/recovery | BPC-157 | Physical therapy, NSAIDs, PRP | Potentially interesting mechanistic profile in animal models | Zero human RCT data; no verified dose for humans; safety profile unknown |
Why Do Storage and Stability Rules Exist for Peptides?
Lyophilized peptides are stable because removing water eliminates the primary degradation pathway: hydrolysis of peptide bonds. Moisture plus heat accelerates this cleavage, shortening shelf life from months to days. Light exposure causes oxidation of methionine and tryptophan residues, which are present in several GHRPs, altering binding affinity at target receptors.
Once you add bacteriostatic water to reconstitute a peptide, you reintroduce the hydrolysis pathway. Refrigeration at 2 to 8 degrees Celsius slows but does not halt this process. The practical consequence: a reconstituted vial used over 60 days may deliver meaningfully less active peptide per dose than a fresh vial, even with correct storage. This is why most compounding pharmacies and researchers recommend using reconstituted peptides within 30 days.
Freeze-thaw cycling damages tertiary and quaternary structure in longer peptides. For short peptides (under 10 amino acids) this matters less because they lack complex folding. For peptides like tesamorelin (44 amino acids), repeated freeze-thaw is a real potency risk. The rule: reconstitute once, refrigerate, and do not refreeze.
Acetic acid (0.1 to 1%) is used as the reconstitution solvent for some peptides because it maintains solubility and provides mild antimicrobial action. Bacteriostatic water (0.9% benzyl alcohol) is more common and appropriate for multi-dose vials. Using plain sterile water creates a sterility risk after the first draw.
How Do You Judge a Peptide Product or Protocol?
Reading a COA. A legitimate certificate of analysis for a research peptide should include: HPLC chromatogram confirming purity greater than 98% (area percent method), mass spectrometry confirming molecular weight within 1 Da of theoretical, LAL endotoxin test confirming less than 1 EU/mg for any injectable preparation, and the name of the independent third-party testing laboratory. If the COA is undated, lacks a lab name, or shows purity by weight (not area percent), treat it as unverified.
Reconstitution math. A common error: a 5 mg vial of CJC-1295 reconstituted with 2 mL of bacteriostatic water yields a concentration of 2,500 mcg/mL. A 200 mcg dose requires 0.08 mL, or 8 units on a U-100 insulin syringe. Confusing mcg and mg when calculating draws is the most common dosing error with research peptides.
| Vial Size | Reconstitution Volume | Concentration | 200 mcg dose = X units (U-100 syringe) |
|---|---|---|---|
| 2 mg | 1 mL | 2,000 mcg/mL | 10 units |
| 5 mg | 2 mL | 2,500 mcg/mL | 8 units |
| 5 mg | 5 mL | 1,000 mcg/mL | 20 units |
What degraded peptide looks like. A cloudy or discolored reconstituted solution (yellow, brown, or with visible particulate) suggests bacterial contamination or oxidative degradation. A correctly stored, sterile reconstituted peptide should be clear and colorless. Do not inject a cloudy peptide solution.
When Does Combining Peptides Make Mechanistic Sense?
The GHRH plus GHRP combination is the most mechanistically defensible stack in this category. GHRH analogs (CJC-1295, tesamorelin) increase the amplitude of GH pulses by acting on pituitary GHRH receptors. GHRPs (ipamorelin, GHRP-2) increase pulse frequency via GHSR-1a. Because these are independent receptor systems, their combination produces a GH response that exceeds either alone. Small human pharmacokinetic studies confirm this synergy, though controlled body-composition outcome trials are absent.
Combining a GLP-1 agonist with a GH secretagogue has theoretical appeal for simultaneous fat loss and lean-mass preservation, but this combination has no published human safety or efficacy data. The interaction between elevated GH/IGF-1 and the metabolic changes induced by GLP-1 agonism is not well characterized. Anyone pursuing this combination is operating well beyond the evidence base.
Stacking BPC-157 with anything for body composition adds no evidence-based rationale and adds unknown risk.
Frequently Asked Questions
Sources
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP-1)
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. (SELECT trial)
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. (Tesamorelin RCT)
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. (MK-677)
- Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. (Animal/mechanistic review)
- World Anti-Doping Agency. Prohibited List 2024. WADA, 2024. (Growth hormone releasing peptides listed under S2)
- US Food and Drug Administration. Egrifta SV (tesamorelin) prescribing information. 2019.
- Jastreboff AM, et al. Tirzepatide vs. Semaglutide for Obesity. N Engl J Med. 2025. (SURMOUNT-5)